Basic Information

Gene symbol MS4A1 Synonyms B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 Type of gene protein-coding
Description membrane spanning 4-domains A1

GTO ID GTC0158
Trial ID NCT01735604
Disease Diffuse Large B-Cell Lymphoma | Follicular Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Mantle Cell Lymphoma
Altered gene CD20
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD20 CAR-T cells
Generation2nd
PhasePhase1|Phase2
Recruitment statusUnknown
TitleGenetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
Year2013
CountryChina
Company sponsorChinese PLA General Hospital
Other ID(s)CHN-PLAGH-BT-001
Vector information
Vectorlentivirus
ConstructscFv-4-1BB-CD3ζ
Transgene/Inserted geneCD20 scFv; human CD137; CD3ζ signaling domains
Viral genome modificationa three-plasmid production approach
Additional featureGFP

Clinical Result

Cohort1: dose level 1
Administration route intravenous infusion
Dosage 1.8~5.5E9 cells/kg
Donor type Autologous
Pts 7
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 1/7(CR); 4/7(PR)
Adverse reactions 4/7(Cytokine release syndrome; Alimentary tract hemorrhage; Sudden tumor lysis syndrome; Acute alimentary tract hemorrhage; Lung dysfunction; Serous cavity effusion)
References PMID: 25444722
Cohort2: dose level 2
Administration route intravenous infusion
Dosage 0.41~1.46E7 cells/kg
Donor type Autologous
Pts 11
Age Adult, Older_Adult
Lymph depletion Yes
Outcome 6/11(CR); 3/11(PR); 2/11(SD)
Adverse reactions 1/11(Hypokalemia; Herpes zoster）
References PMID: 25444722

Relationship Graph

Overview of Knowledge Graph